<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03049839</url>
  </required_header>
  <id_info>
    <org_study_id>55657</org_study_id>
    <nct_id>NCT03049839</nct_id>
  </id_info>
  <brief_title>Evaluation of a Community Health Program for the Prevention of Type 2 Diabetes and Other Cardio-metabolic Risk Factors in Adults: Districts of Barranquilla and Bogota, Colombia - January 2017 - December 2019</brief_title>
  <acronym>PREDICOL</acronym>
  <official_title>Evaluation of a Community Health Program for the Prevention of Type 2 Diabetes and Other Cardio-metabolic Risk Factors in Adults: Districts of Barranquilla and Bogota, Colombia - January 2017 - December 2019</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad del Norte</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad del Norte</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of this study is to evaluate the feasibility and effectiveness of a program for&#xD;
      modifying lifestyles for diabetes prevention type 2 and control cardio-metabolic risk factors&#xD;
      in adults with different categories of risk from the primary health care strategy.&#xD;
&#xD;
      The project will show the effect of these interventions for the first time in people With&#xD;
      different risk of developing type 2 diabetes throughout the life in populations living in&#xD;
      Colombia Located in 2 different cities, one of them in the interior of the country (districts&#xD;
      of Bogota) and another in the north coast (districts of Barranquilla) .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease (CVD) and type 2 diabetes (T2D) are currently the public health&#xD;
      problems fastest growing globally. According to the International Diabetes Federation (IDF)&#xD;
      is estimated to have diabetes approximately 382 million people in the world. It is shown that&#xD;
      early interventions in lifestyle can reduce the burden of type 2 diabetes and factors of&#xD;
      cardiovascular modifiable risk.&#xD;
&#xD;
      This is an intervention study in cluster. 36-month integrated into 4 phases:&#xD;
&#xD;
        1. Design and adaptation of educational intervention&#xD;
&#xD;
        2. Population Screening&#xD;
&#xD;
        3. Stepwise intervention program&#xD;
&#xD;
        4. Evaluation results.&#xD;
&#xD;
      For population screening test FINDRISC validated for the Latin American population will be&#xD;
      employed and a score of 12 will be considered as a cutoff to all who have a score equal to or&#xD;
      greater than 12 (moderate or high risk) they perform a test oral glucose tolerance (OGTT)&#xD;
      according to the results 3 groups will be established&#xD;
&#xD;
        -  High risk group: Subjects with FINDRISC score ≥12 and impaired glucose tolerance (IGT)&#xD;
&#xD;
        -  Moderate risk group: Subjects with FINDRISC score ≥12 and impaired fasting glucose or&#xD;
           norm tolerant&#xD;
&#xD;
        -  Low risk group: Subjects with FINDRISC score &lt;12.&#xD;
&#xD;
      Intervention program: One year of duration, 3 types of programs are established.&#xD;
&#xD;
        -  Lifestyle Intervention program_ Communitarian: Intervention program at Community level&#xD;
           with Low risk group.&#xD;
&#xD;
        -  Lifestyle Intervention program_ Informative: Program information intervention for the&#xD;
           group with moderate risk.&#xD;
&#xD;
        -  Lifestyle Intervention program_ structured: intervention program for members of&#xD;
           high-risk group.&#xD;
&#xD;
      An evaluation of the different variables are studied at baseline and the final of the&#xD;
      intervention in the three groups established.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of body weight average at year-end structured intervention compared with the baseline.</measure>
    <time_frame>12 Months</time_frame>
    <description>Reduction of body weight in kilograms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of fasting glucose level at year-end intervention program (all groups) compared with baseline.</measure>
    <time_frame>12 Months</time_frame>
    <description>Reduction of fasting glucose level in mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of 2-hour glucose level at year-end structured and informative intervention program compared with baseline.</measure>
    <time_frame>12 Months</time_frame>
    <description>Reduction of 2-hour glucose level in mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced of waist circumference average at year-end structured intervention program compared with baseline.</measure>
    <time_frame>12 Months</time_frame>
    <description>Reduction of waist circumference in centimeters</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">650</enrollment>
  <condition>Prediabetic State</condition>
  <arm_group>
    <arm_group_label>Intervention_ structured</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One year Structured intervention program for members of high-risk group (People with glucose intolerance in the OGTT and FINDRISC score ≥12 points) 10 educational group sessions where they will receive information to change lifestyle (1 per 1.5 month)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention_ Informative</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Program information intervention for the group with moderate risk. One year Informative intervention program (People with normotolerant or impaired fasting glucose in the OGTT and FINDRISC score ≥12 points).&#xD;
There is a single group session where they receive information to prevent cardiomatabolic risk factors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention_ Communitarian</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One year, Intervention program at Community level. People with a FINDRISC less than 12 points.&#xD;
Campaigns are carried out at the community level with different strategies (leaflets, booklets) to prevent cardiomatabolic risk factors</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intervention_ S</intervention_name>
    <description>One year Structured intervention program for members of high-risk group (Subjects with FINDRISC score ≥12 points and impaired glucose tolerance (IGT))</description>
    <arm_group_label>Intervention_ structured</arm_group_label>
    <other_name>LIP_Structures</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intervention_ I</intervention_name>
    <description>One year Informative intervention program for members of moderate risk group (People with normotolerant or impaired fasting glucose in the OGTT and a FINDRISC score ≥12 points)</description>
    <arm_group_label>Intervention_ Informative</arm_group_label>
    <other_name>LIP_Informative</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intervention_ C</intervention_name>
    <description>One year, Intervention program at Community level. People with a FINDRISC less than 12 points</description>
    <arm_group_label>Intervention_ Communitarian</arm_group_label>
    <other_name>LIP_Communitarian</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  People over age 30 years, residents within the perimeter of the conglomerate in the&#xD;
             districts of Barranquilla and Bogota&#xD;
&#xD;
          -  Wishing to participate and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  DT2 known and / or treated&#xD;
&#xD;
          -  History of diseases or events that prevent their participation&#xD;
&#xD;
          -  Neurological disability that does not allow you to make own decisions&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tania Acosta, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad del Norte</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Achner, MD, ENDOCRINOLOGIST</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASOCIACIÓN COLOMBIANA DE DIABETES</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tania Acosta</last_name>
    <phone>00573106331321</phone>
    <email>tacosta@uninorte.edu.co</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pablo Aschner</last_name>
    <phone>00573106331321</phone>
    <email>pabloaschner@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universidad Del Norte</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>tania Acosta, MD, MPH, PhD</last_name>
      <phone>00573106331321</phone>
      <email>tacosta@uninorte.edu.co</email>
    </contact>
    <investigator>
      <last_name>Tania Acosta, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edgar Navarro, MD, MSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jorge Acosta, MD, MSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rafael Tuesca, MD, PhD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Rodriguez, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jesus Arroyabe, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karen Florez, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Caro, MSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariela Borda, MSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asociación Colombiana de Diabetes</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Aschner, MD</last_name>
      <phone>00573102118652</phone>
      <email>pabloaschner@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pablo Aschner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dilcia Lujan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margot Latino</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liliana Carvajal</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patricia Barrera</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Ronderos</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>October 21, 2016</study_first_submitted>
  <study_first_submitted_qc>February 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2017</study_first_posted>
  <last_update_submitted>March 8, 2019</last_update_submitted>
  <last_update_submitted_qc>March 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

